Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: A Subset analysis of TAX 324

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 5, 2011, Pages

  Sher, David J ^a   Posner, Marshall R ^b   Tishler, Roy B ^a   Sarlis, Nicholas J ^c   Haddad, Robert I ^a   Holupka, Edward J ^d   Devlin, Phillip M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Chemoradiotherapy; Head and neck cancer; Induction chemotherapy; Radiation field design; Radiation treatment time

Indexed keywords

CHEMORADIOTHERAPY; HEAD-AND-NECK CANCER; INDUCTION CHEMOTHERAPY; RADIATION FIELD DESIGN; RADIATION TREATMENT TIME;

CHEMOTHERAPY; OPTIMIZATION; PLATINUM COMPOUNDS; QUALITY ASSURANCE; RADIOTHERAPY; TAXATION;

ECONOMIC ANALYSIS;

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; FEMALE; HAZARD RATIO; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOCALLY ADVANCED HEAD AND NECK CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RADIATION DOSE; SECONDARY ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS;

EID: 81855184922     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.12.005     Document Type: Article

References (15)

1. D.J. Adelstein, Y. Li, and G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 2003 92 98
2. A.A. Forastiere, H. Goepfert, and M. Maor Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 2003 2091 2098 (Pubitemid 37464533)
3. D.M. Brizel, and E.E. Vokes Induction chemotherapy: To use or not to use? That is the question Semin Radiat Oncol 19 2009 11 16
4. M.R. Posner, D.M. Hershock, and C.R. Blajman Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 2007 1705 1715 (Pubitemid 350005152)
5. J.B. Vermorken, E. Remenar, and C. van Herpen Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 2007 1695 1704 (Pubitemid 350005151)
6. A. Eisbruch Commentary: Induction chemotherapy for head and neck cancer: Hypothesis-based rather than evidence-based medicine Oncologist 12 2007 975 977 (Pubitemid 47359140)
7. M.L. Citron, D.A. Berry, and C. Cirrincione Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439 (Pubitemid 46594092)
8. M.E. Alden, R.C. O'Reilly, and A. Topham Elapsed radiation therapy treatment time as a predictor of survival in patients with advanced head and neck cancer who receive chemotherapy and radiation therapy Radiology 201 1996 675 680 (Pubitemid 26392613)
9. K.K. Ang, J. Harris, and R. Wheeler Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35
10. H.R. Withers, J.M. Taylor, and B. Maciejewski The hazard of accelerated tumor clonogen repopulation during radiotherapy Acta Oncol 27 1988 131 146
11. K.K. Fu, T.F. Pajak, and A. Trotti A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16 (Pubitemid 30488207)
12. J. Bourhis, J. Overgaard, and H. Audry Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis Lancet 368 2006 843 854 (Pubitemid 44292807)
13. J. Overgaard, H.S. Hansen, and L. Specht Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial Lancet 362 2003 933 940 (Pubitemid 37159288)
14. E. Ben-Josef, J. Moughan, and J.A. Ajani Impact of overall treatment time on survival and local control in patients with anal cancer: A pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11 J Clin Oncol 28 2010 5061 5066
15. D. De Ruysscher, M. Pijls-Johannesma, and S.M. Bentzen Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer J Clin Oncol 24 2006 1057 1063 (Pubitemid 46638802)